FDA Grants Priority Review Status to Opdivo Application for Advanced Liver Cancer Patients
Liver cancer, News
The U.S. Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Application (sBLA) submitted by Bristol-Myers Squibb seeking approval for Opdivo (nivolumab) to treat patients with ... Read more